Prof. Wei Huang 黄伟
Chief Physician, Professor
Department of Thoracic Radiation Oncology I, Cancer Hospital of Shandong First Medical University (Shandong Cancer Hospital), Jinan
Public profile Compiled from public listings and PubMed. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionClinical focus: Radiation therapy and comprehensive treatment for esophageal cancer, breast cancer, and lung cancer.
Dr. Huang is Director of Chest Radiation Therapy Ward 5 at Shandong Cancer Hospital and a professor at Shandong University and Shandong First Medical University. A visiting scholar at the Medical College of Wisconsin, Dr. Huang was a main drafter of Chinese guidelines for esophageal and breast cancer radiation therapy. Research focuses on precise radiation therapy and molecular functional imaging.
Professional roles
- Group Leader, Chinese Medical Association
- Vice Chair, Youth Committee of Radiation Oncology Branch, Chinese Medical Doctor Association
- Deputy Group Leader, Breast Cancer Group, Radiation Oncology Branch, Chinese Medical Association
- Member, Youth Group and Immunology Group, Radiation Oncology Branch, Chinese Medical Association
Name order: in Chinese the family name comes first (Huang Wei). Papers usually list the name as Wei Huang or Huang W.
Selected publications
125 papers on PubMed matched by name and affiliation; 25 as first or senior author since 2016. Most recent first- or senior-author papers:
- Cancer Genet, 2026 (senior author): Concurrent chemoradiotherapy with or without simultaneous integrated boost for unresectable stage III non-small-cell lung cancer: a randomized phase II trial with exploratory EGFR and PD-L1 analyses. PubMed 42456525
- Ther Adv Med Oncol, 2026 (senior author): Efficacy comparison of first-line treatment regimens for stage IV esophageal squamous cell carcinoma with supraclavicular lymph node metastasis: A study of the oligometastatic subtype. PubMed 42668696
- Cancer Immunol Res, 2026 (senior author): Induction Serplulimab and Chemotherapy Followed by Chemoradiotherapy for Bulky Unresectable Stage III NSCLC: A Phase II Study (SUCCEED-01). PubMed 41911546
- Signal Transduct Target Ther, 2026 (senior author): Sintilimab plus concurrent chemoradiotherapy for treatment of locally advanced small cell lung cancer (SINCE-01): a phase II clinical trial. PubMed 42225651
- J Cancer Res Ther, 2025 (senior author): Effect of radical radiotherapy dose on the prognosis of limited-stage thoracic small cell carcinoma of the esophagus: A multicenter retrospective trial from China (CHiSCEC). PubMed 40905869
- Front Med (Lausanne), 2025 (senior author): Immunotherapy in advanced esophageal squamous cell cancer: earlier or later?. PubMed 40703253
- Future Oncol, 2024 (senior author): Tislelizumab for consolidation therapy in patients with pathologically residual Esophageal Squamous Cell Carcinoma after definitive concurrent Chemoradiotherapy: a multicenter, randomized, controlled phase II trial. PubMed 39589855
- Cell Oncol (Dordr), 2024 (senior author): HNRNPH1 stabilizes FLOT2 mRNA in a non-canonical m6A-dependent manner to promote malignant progression in nasopharyngeal carcinoma. PubMed 39570559
See the full PubMed search. Automatic matching can miss papers or include a namesake at the same hospital. This name is shared by other researchers, so we checked that the papers match this doctor's specialty; this check is automatic.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and write a treatment plan with a cost estimate.
Get a specialist opinion